摘要
通过文献综述,发现抗血小板聚集药物在心血管疾病中有良好应用,但其出血不良反应仍存在,一些新药机制不明确。因此,抗血小板聚集的机制研究还需加快。一种新型的抗血小板聚集药物终将诞生,如EP3受体抑制剂,为新抗血小板聚集药物的研究提供思路。
The latest literatures showed that the anti-platelet aggregation drugs had a good application in cardiovascular disease,however still with hemorrhage side effects and some new drugs＇ mechanism was unknown. So further investigations on the mechanism of anti-platelet aggregation are necessary to discover a new type of anti-platelet drugs,such as antagonists of the EP3 receptor.
出处
《中国康复理论与实践》
CSCD
2010年第10期954-957,共4页
Chinese Journal of Rehabilitation Theory and Practice
基金
"重大新药创制"科技重大专项(2009ZX09103-366)
国家自然科学基金项目(30740053
309773893)
北京市自然科学基金项目(7062031)
关键词
抗血小板聚集药物
机制
综述
anti-platelet aggregation drugs
mechanism
review
